Chen Zhang, Peng Tu, Xiangyu Jia, Yuanfeng Xia, Biao Lu, Fanglong Yang, Siqin Wang, Lei Jin
{"title":"Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer","authors":"Chen Zhang, Peng Tu, Xiangyu Jia, Yuanfeng Xia, Biao Lu, Fanglong Yang, Siqin Wang, Lei Jin","doi":"10.1021/acsmedchemlett.4c00383","DOIUrl":null,"url":null,"abstract":"A novel class of kinesin KIF18A inhibitors were discovered through modification of the clinical compound AMG650. Structure–activity relationship (SAR) study led to the discovery of compound <b>16</b> with an alkenyl motif, a highly potent KIF18A inhibitor, which displayed a favorable pharmacological profile and excellent efficacy in a mouse model of an OVCAR-3 xenograft tumor. Oral administration of <b>16</b> can induce a dose-dependent antitumor efficacy in the OVCAR-3 model without significant reduction in body weight. Compound <b>16</b> showed potential as a candidate for the clinical treatment of ovarian cancer.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":"31 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsmedchemlett.4c00383","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
A novel class of kinesin KIF18A inhibitors were discovered through modification of the clinical compound AMG650. Structure–activity relationship (SAR) study led to the discovery of compound 16 with an alkenyl motif, a highly potent KIF18A inhibitor, which displayed a favorable pharmacological profile and excellent efficacy in a mouse model of an OVCAR-3 xenograft tumor. Oral administration of 16 can induce a dose-dependent antitumor efficacy in the OVCAR-3 model without significant reduction in body weight. Compound 16 showed potential as a candidate for the clinical treatment of ovarian cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
